Pharsight Builds Momentum in DMX® Product, Signs deCODE Genetics
News Feb 07, 2006
The license agreement with deCODE is the latest Pharsight has closed with leading pharmaceutical companies in Europe and the United States.
DMX is a software tool that is designed to allow clinical drug development teams to explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies.
"We hope to use DMX to drive faster and more confident drug-development decisions at deCODE," said David Hermann, PharmD, Executive Director of Pharmacometrics at deCODE.
"We expect to use DMX to rapidly display our latest modeling results and make our development decisions clear to the entire team."
Daniel L. Hartman, M.D., Senior Vice President of Product Development at deCODE added, "Quantitative modeling and simulation offers a valuable set of approaches to help navigate the myriad trade-offs and complexities that inform key program decisions."
"We look forward to using DMX to explore model-based results and support the decision-making process for promising therapies in our pipeline."
"DMX's intuitive presentation of modeling insights is especially useful when a new drug faces tough competition," said Shawn O'Connor, Pharsight president and chief executive officer.
"We are pleased that deCODE recognizes the contribution that quantitative drug-disease modeling, combined with novel visualization and communication technology like DMX, can make to improve decision-making."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.